India to Canada: Anastrozole Export Trade Route

To import Anastrozole formulations into Canada, the following approvals and registrations are necessary:

• Drug Identification Number (DIN): Each pharmaceutical product must obtain an eight-digit DIN from Health Canada before it can be marketed in Canada. This number signifies that the product has been evaluated and authorized for sale. (canada.ca)

• Drug Establishment Licence (DEL): Importers must hold a valid DEL for the activity of importation. The foreign manufacturing site must be listed on the importer's DEL. (canada.ca)

• Good Manufacturing Practices (GMP) Compliance: The foreign manufacturing facility must comply with Health Canada's GMP standards. Compliance is verified through inspections, and the facility must be listed on the importer's DEL. (canada.ca)

• Submission Format: Health Canada requires submissions in the Common Technical Document (CTD) format.

• Timelines and Fees: Approval timelines and product registration fees can vary. It is advisable to consult Health Canada's official guidelines or contact them directly for the most current information.

Indian manufacturers exporting Anastrozole formulations to Canada must adhere to the following GMP standards:

• GMP Certification: Manufacturers must comply with Health Canada's GMP requirements, which align with international standards. (canada.ca)

• Facility Approval: The manufacturing facility must be listed on the Canadian importer's DEL, indicating that it has been inspected and deemed compliant by Health Canada. (canada.ca)

• Recent Inspections: Health Canada regularly inspects foreign manufacturing sites to ensure ongoing compliance. Specific details about recent inspections or regulatory actions against Indian pharmaceutical companies are not publicly disclosed. However, manufacturers are expected to maintain compliance to avoid potential regulatory actions.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to Canada:

• Revised GMP Rules in India: In January 2024, India's Ministry of Health revised its GMP regulations to align more closely with global standards, including those of the World Health Organization. This revision aims to enhance the quality of pharmaceutical products and facilitate international trade.

• Health Canada's Enhanced Oversight: Effective December 8, 2022, Health Canada amended the Food and Drug Regulations to extend DEL and GMP requirements to drugs manufactured or prepared in Canada solely for export. This change strengthens oversight and aligns Canadian regulations with international practices.

These developments underscore the importance of compliance with updated GMP standards and regulatory requirements for Indian exporters aiming to supply pharmaceutical products to the Canadian market.

Anastrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. In Canada, the prevalence of breast cancer remains significant, with approximately 28,000 new cases diagnosed annually as of 2024. The aging population and universal healthcare coverage contribute to a steady demand for effective treatments like Anastrozole. While specific market size data for Anastrozole in Canada for 2024-2025 is not readily available, the consistent incidence rates and treatment protocols suggest a stable market. Canada's pharmaceutical industry includes both domestic manufacturing and imports to meet demand. The import data indicates that Canada sources finished Anastrozole formulations from international suppliers, including India, to supplement domestic production.

Canada applies a 0% MFN tariff rate on pharmaceutical products under HS code 30049099, encompassing finished Anastrozole formulations. This means that imports of these products from India and other countries are duty-free. Additionally, Canada has free trade agreements (FTAs) with several countries, but as of March 2026, there is no comprehensive FTA between Canada and India that affects pharmaceutical tariffs. Therefore, the 0% MFN tariff applies to Anastrozole imports from India. Goods and Services Tax (GST) is applicable on imported goods, including pharmaceuticals, calculated on the total value for tax, which includes the value for duty plus any applicable customs duty and surtax. However, since the MFN tariff rate for these products is 0%, the GST is calculated solely on the value for duty. There are no specific anti-dumping duties imposed on Anastrozole imports into Canada as of the latest available data.

India is a significant supplier of finished Anastrozole formulations to Canada, accounting for approximately 1.0% of India's total Anastrozole formulation exports, valued at $1.2 million USD across 43 shipments. The top Indian exporters include Sun Pharmaceutical Industries Limited and Natco Pharma Limited. In Canada, major buyers of these imports are Accord Healthcare Inc. and Marcan Pharmaceuticals Inc. While specific data on other countries supplying Anastrozole to Canada is not provided, the global Anastrozole market includes manufacturers from the European Union and China. India's pharmaceutical industry is known for its cost-effective manufacturing capabilities, often offering competitive pricing compared to European and Chinese manufacturers. This pricing advantage, combined with the 0% MFN tariff, positions Indian suppliers favorably in the Canadian market for Anastrozole formulations.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. As of November 2024, India had 396 facilities registered under the U.S. FDA's Generic Drug User Fee Amendments (GDUFA), the highest number globally.

Several Indian manufacturers have received approvals from stringent regulatory authorities, including the U.S. FDA and the European Medicines Agency (EMA), for their finished dosage forms containing Anastrozole. For instance, in November 2025, Granules India Limited announced that its subsidiary, Granules Life Sciences Private Limited, received U.S. FDA approval for a product manufactured at its Hyderabad facility.

The cost advantages of sourcing Anastrozole formulations from India are significant. The country's efficient manufacturing processes and economies of scale enable competitive pricing for finished dosage forms such as tablets and capsules. Additionally, India's pharmaceutical sector benefits from a well-established supply chain and a skilled workforce, further enhancing its manufacturing capabilities.

When comparing Anastrozole formulation exports from India, China, and the European Union (EU), several factors come into play, including cost, quality perception, regulatory acceptance in Canada, and supply reliability.

In terms of cost, Indian manufacturers offer competitive pricing for Anastrozole finished dosage forms. For example, the National Average Drug Acquisition Cost (NADAC) in the U.S. for Anastrozole tablets manufactured by Aurobindo Pharma Limited was $0.14605 per unit as of December 17, 2025. In contrast, branded versions like ARIMIDEX had an average pharmacy acquisition cost of approximately $52.60 per unit in January 2026.

Quality perception and regulatory acceptance are crucial for market entry into Canada. Indian pharmaceutical companies have a strong track record of compliance with international quality standards, with numerous facilities approved by the U.S. FDA and EMA. This compliance facilitates the acceptance of Indian-manufactured Anastrozole formulations in Canada.

Supply reliability is another critical factor. Indian manufacturers have demonstrated a consistent ability to meet global demand for Anastrozole formulations, supported by robust manufacturing capacities and established supply chains. While Chinese manufacturers are also significant players in the generic pharmaceutical market, India's extensive regulatory approvals and established presence in international markets provide a competitive edge.

The India-Canada supply chain for Anastrozole formulations is characterized by reliability and substantial manufacturing capacity. Indian pharmaceutical companies have invested in state-of-the-art facilities to produce finished dosage forms, including Anastrozole tablets and capsules. For instance, Akums Drugs and Pharmaceuticals operates multiple units in Haridwar, with European GMP certifications for solid oral dosage forms and parenterals.

Packaging and cold chain capabilities are well-developed, ensuring the integrity of pharmaceutical products during transit. Indian manufacturers adhere to stringent regulatory compliance, with facilities regularly inspected and approved by international authorities such as the U.S. FDA and EMA.

As of March 2026, there have been no significant supply disruptions reported in the India-Canada Anastrozole formulation supply chain. Manufacturers continue to expand their capacities to meet growing global demand. For example, Granules India Limited's Hyderabad facility received U.S. FDA approval in November 2025, enhancing its production capabilities.

For Canadian buyers sourcing Anastrozole formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Anastrozole formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements on order sizes to align with both supplier capabilities and buyer requirements.

• Payment Terms: Standard payment terms in India-Canada pharmaceutical trade often include letters of credit or advance payments. Negotiate terms that balance financial security with cash flow considerations.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory approvals, and assessment of quality control systems, to ensure compliance with Canadian regulatory standards.

• Regulatory Compliance: Ensure that selected suppliers have the necessary approvals from Health Canada and other relevant authorities to facilitate smooth importation and distribution within Canada.

By implementing these strategies, Canadian buyers can effectively source high-quality Anastrozole formulations from India, leveraging the country's manufacturing advantages and ensuring a reliable supply chain.

By adhering to this comprehensive approach, Canadian companies can effectively qualify Indian suppliers of Anastrozole formulations, ensuring compliance with regulatory standards and maintaining product quality.